Oct 7 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:
BIOMARIN PHARMACEUTICAL INC: EXPECTS Q3 WILL INCLUDE ACQUIRED IPR&D CHARGES OF APPROXIMATELY $221 MILLION ON A PRE-TAX BASIS DUE TO INOZYME PHARMA DEAL
BIOMARIN PHARMACEUTICAL INC - FOR Q3, CO EXPECTS CHARGE OF ABOUT $1.10 TO BOTH GAAP AND NON-GAAP EPS DUE TO INOZYME PHARMA DEAL